- In April 2024, Merck KGaA (Germany) expanded its cell culture media production facility in Darmstadt to meet growing regional demand for high-quality, GMP-compliant media used in biologics and vaccine manufacturing. The expansion reflects Merck’s commitment to bolstering Europe's biopharmaceutical supply chain resilience and its role as a key supplier to advanced therapy manufacturers across the continent
- In March 2024, Sartorius AG (Germany) announced the launch of a new portfolio of chemically defined media tailored for stem cell and CAR-T cell applications. Developed in collaboration with leading academic partners, the product line supports scalable manufacturing of next-generation therapies and enhances reproducibility and regulatory compliance in cell therapy production workflows
- In February 2024, Lonza Group AG (Switzerland) opened a new research and development hub in Visp focused on the innovation of specialty media formulations for immunotherapy and regenerative medicine. This strategic move aims to accelerate product development for European clients involved in cutting-edge cell-based research and advanced biologics manufacturing
- In February 2024, Thermo Fisher Scientific (operational across Europe) collaborated with the University of Oxford to co-develop customized culture media for neuroscience and organoid research. The initiative supports academic research by providing targeted formulations that improve cell viability and experimental consistency, reinforcing the company’s strong academic-industry ties in the region
- In January 2024, PAN-Biotech GmbH (Germany) introduced a new GMP-grade serum-free medium specifically designed for mesenchymal stem cell expansion. This launch aims to support clinical-grade production of cell-based therapies and reflects growing demand in Europe for xeno-free, scalable media solutions that meet both research and regulatory needs
